Artivion acquires medtech company behind FDA-approved endovascular device for $135M
Artivion, an Atlanta-based medtech company focused on cardiac and vascular technologies, has finalized its acquisition of Israel-based Endospan for approximately $135 million. The purchase price could potentially increase to $200 million if certain commercial milestones are met going forward.
Endospan is known for its Nexus Aortic Arch System, a branched endovascular stent graft system secured for the treatment of aortic arch disease back. The device secured FDA approval in April based on data from the NEXUS TRIOMPHE trial, which linked its use to positive one-year findings in terms of survival, disabling stroke and reinterventions.
“The FDA approval of the Nexus system was a pivotal moment for aortic surgeons seeking a technology specifically designed to treat the ascending and aortic arch,” Kevin Mayberry, CEO of Endospan, said in a statement. “With Artivion’s acquisition of Endospan, this differentiated technology is being positioned within a company that understands the aortic space through a differentiated portfolio serving the multidisciplinary approach of open, endo and hybrid solutions.”
“Nexus is a platform technology, not just a single product,” added Pat Mackin, chairman president and CEO of Artivion. “With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”
Artivion had already been partnering with Endospan for years when the FDA approved the Nexus device. Once that approval was in place, however, it allowed Artivion to exercise its option to acquire Endospan. In early May, Artivion officially told investors it would be exercising that option—and now the acquisition is final.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.